-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Constellation Energy is preparing to restart what's now called the Crane Clean Energy Center on Three Mile Island to supply ...

DelveInsight's Glucose Syrup Market Insights report provides the current and forecast market analysis, individual leading ...

DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...